All News

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.

Nicholas Blondin, MD, discusses the latest advancements in immunotherapy for brain cancer as well as emerging strategies, including CAR T-cell therapy.

Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.

At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Joseph C. Landolfi, DO, CPE, and Michele Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.

Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

Findings from prior studies, such as the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.

Leaders of a new cancer center, which is part of JFK University Medical Center, discuss how they can support frontline clinicians.

CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.